Searched for
PATENT PORTFOLIO
Haircare startup Xtovia raises Rs 6.9 crore led by V3 VenturesFounded in 2025 by entrepreneur Navneet Misra and Dr Tunga Madhu Babu, who heads research and development and holds a PhD from IIT Madras, ...- Warren Buffett on stock market: Fools give you reasons, wise men never tryWarren Buffett gave himself a D in capital allocation – his worst grade ever. But the confession came along with a warning that would prove...
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Deeptech VC YourNest closes Rs 400 crore continuation fundYourNest Venture Capital has launched a Rs 400 crore continuation fund, YourNest Continuum Fund I, anchored by HDFC AMC. This fund will inv...
- Jio enters global top 20 list in WIPO patent rankingsJio Platforms has surged into the global top 20 of WIPO's PCT rankings, a remarkable leap of 320 positions. This achievement highlights Jio...
- He is 83, loves The Beatles, Billy Joel. Elon Musk calls him 'smart'? Who is Ron Baron and how much the investor will make from SpaceX shares?As SpaceX makes it historic Nasdaq debut, veteran investor Ron Baron emerged as one of the company's biggest champions. The 83-year-old bil...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Beyond the prompt: The rise of the agentic organisationAI is evolving beyond assistants to become autonomous agents. This shift requires enterprises to redesign their operations. New goal-driven...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Hindustan Labs, RK Steel get Sebi nod to launch IPOsHindustan Laboratories has received Sebi's observations, a crucial step towards its IPO, which includes a fresh issue and an offer for sale...
- Tata Motors files record 144 patent applications in FY26Tata Motors achieved a record with 144 patent applications in FY26. These innovations target vehicle safety, reliability, and occupant comf...
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- Pharma calls in sick after Trump’s 100% tariff threatPharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...
Load More
